Margaret Karow

Margaret Karow brings over 25 years of experience in the generation and engineering of protein therapeutics. Prior to joining Tentarix, Margaret was the CSO for Gensun Biopharma. For the prior 3 years, she was the Senior Vice President of Pre-Clinical Development for Xilio Therapeutics, (formerly Akrevia Therapeutics) where she delivered milestones that led to $30M Series A funding. Before joining Xilio Therapeutics, she was an Executive Director at Amgen for 10 years, and held multiple positions including leadership roles for Biosimilars Process Development, Amgen Thousand Oaks Protein Sciences, Biologics Optimization, and Site Head for Amgen Burnaby, Canada. Margaret started her career in biotech at Regeneron, with various roles over her 10 years, including Vice President of Traps, Small Molecule, Antibody Development, and Immunology, and was a co-lead for the development of the VelocImmune mouse platform.

Margaret received her Ph.D. from CVMBiology at the Univ. of Utah, and BA in MCDBiology from the Univ. of Colorado, Boulder.